Atlas Trials

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

Clinical trial NCT03399513 · COMPLETED

Trial details

NCT number
NCT03399513
Sponsor
University Hospital Muenster
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell Lymphoma
Start date
2018-05-03
Primary completion
2023-12-23
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.